Melphalan
Information
- Drug Name
- Melphalan
- Description
- Entry(CIViC)
- 17
CIViC
Annotation
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04339101 | Active, not recruiting | Phase 2 | Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation | November 11, 2020 | May 22, 2024 |
| NCT01526096 | Active, not recruiting | Phase 1 | Stem Cell Transplantation for Patients With Multiple Myeloma | July 12, 2011 | September 12, 2025 |
| NCT03346135 | Active, not recruiting | Phase 2 | Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma | July 17, 2019 | July 17, 2025 |
| NCT00003042 | Active, not recruiting | Phase 2 | Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer | May 30, 1997 | December 30, 2024 |
| NCT04872595 | Active, not recruiting | Phase 2 | A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant | April 30, 2021 | April 2025 |
| NCT01476839 | Active, not recruiting | Phase 1 | Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma | November 9, 2012 | December 31, 2024 |
| NCT00114101 | Active, not recruiting | Phase 3 | Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant | December 15, 2004 | February 22, 2025 |
| NCT02195479 | Active, not recruiting | Phase 3 | A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma | December 9, 2014 | June 30, 2024 |
| NCT04395222 | Active, not recruiting | Phase 2 | Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation | October 7, 2020 | May 2027 |
| NCT04191187 | Active, not recruiting | Phase 2 | Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies | December 6, 2019 | February 2025 |
| NCT02866136 | Active, not recruiting | Phase 2 | Conservative Treatments of Retinoblastoma | February 2012 | September 2035 |
| NCT02061800 | Active, not recruiting | Phase 1/Phase 2 | CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant | June 3, 2013 | July 2026 |
| NCT03786783 | Active, not recruiting | Phase 2 | Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | March 4, 2019 | September 22, 2024 |
| NCT01175356 | Active, not recruiting | Phase 1 | Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin | October 4, 2010 | September 28, 2024 |
| NCT04342572 | Active, not recruiting | Phase 1 | Intra-arterial Chemotherapy for Retinoblastoma | August 11, 2020 | January 4, 2025 |
| NCT01163357 | Active, not recruiting | Phase 1 | Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma | January 28, 2011 | December 31, 2024 |
| NCT01885689 | Active, not recruiting | Phase 2 | Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia | February 10, 2014 | December 30, 2024 |
| NCT03691376 | Active, not recruiting | Phase 1 | Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | March 8, 2019 | January 24, 2027 |
| NCT03849651 | Active, not recruiting | Phase 2 | TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies | January 31, 2019 | July 1, 2025 |
| NCT03342196 | Active, not recruiting | Phase 2 | Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation | March 21, 2018 | June 9, 2025 |
| NCT03292263 | Active, not recruiting | Phase 1/Phase 2 | ASCT With Nivolumab in Patients With Multiple Myeloma | April 24, 2017 | December 30, 2024 |
| NCT01091831 | Active, not recruiting | Phase 3 | Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects | July 2009 | December 2024 |
| NCT01857934 | Active, not recruiting | Phase 2 | Therapy for Children With Advanced Stage Neuroblastoma | July 5, 2013 | December 2024 |
| NCT01085617 | Active, not recruiting | Phase 3 | Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | December 2010 | December 2025 |
| NCT03259503 | Active, not recruiting | Phase 1 | Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant | September 13, 2019 | July 31, 2024 |
| NCT03188172 | Active, not recruiting | Phase 2 | MUK Nine b: OPTIMUM Treatment Protocol | September 28, 2017 | May 31, 2026 |
| NCT02797470 | Active, not recruiting | Phase 1/Phase 2 | Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant | June 23, 2016 | June 30, 2025 |
| NCT02443077 | Active, not recruiting | Phase 3 | Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | October 12, 2016 | May 10, 2025 |
| NCT03004287 | Active, not recruiting | Phase 2 | 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy | July 1, 2017 | October 2025 |
| NCT03742297 | Active, not recruiting | Phase 3 | Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years | October 22, 2018 | January 2031 |
| NCT01840566 | Active, not recruiting | Phase 1 | High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma | April 2013 | April 2025 |
| NCT03674411 | Active, not recruiting | Phase 2 | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | January 2, 2019 | June 28, 2024 |
| NCT03821610 | Active, not recruiting | Phase 2 | A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC) | November 22, 2018 | November 22, 2027 |
| NCT02415413 | Active, not recruiting | Phase 2 | Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma | May 2015 | June 2027 |
| NCT01054196 | Active, not recruiting | Phase 1/Phase 2 | Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study | August 2010 | December 2024 |
| NCT01810588 | Active, not recruiting | Phase 2 | Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation | October 16, 2012 | April 2028 |
| NCT00871013 | Active, not recruiting | Phase 2 | Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy | March 2009 | December 2024 |
| NCT01798004 | Active, not recruiting | Phase 1 | Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | April 8, 2013 | |
| NCT01758328 | Active, not recruiting | Phase 1 | Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma | December 2012 | December 2024 |
| NCT02342782 | Active, not recruiting | Phase 1 | Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma | June 8, 2020 | December 31, 2024 |
| NCT02251821 | Active, not recruiting | Phase 2 | JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis | October 20, 2014 | December 28, 2025 |
| NCT00869232 | Active, not recruiting | Phase 2 | UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission | October 2008 | October 2024 |
| NCT00716066 | Active, not recruiting | Phase 2 | Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases | June 2008 | January 31, 2030 |
| NCT00638898 | Active, not recruiting | Phase 1 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | February 26, 2007 | December 30, 2024 |
| NCT03352765 | Active, not recruiting | Phase 1 | A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients | November 20, 2017 | November 2024 |
| NCT02909036 | Active, not recruiting | Phase 1 | Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. | September 2016 | September 2024 |
| NCT00602641 | Active, not recruiting | Phase 3 | Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma | February 29, 2008 | February 22, 2025 |
| NCT00544115 | Active, not recruiting | Phase 2 | Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders | October 16, 2001 | December 30, 2024 |
| NCT00544466 | Active, not recruiting | Phase 1/Phase 2 | Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies | July 31, 2006 | December 30, 2024 |
| NCT01729091 | Active, not recruiting | Phase 2 | Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma | June 10, 2013 | June 30, 2025 |
| NCT04473911 | Active, not recruiting | Phase 1 | Haplo Peripheral Blood Sct In GVHD Prevention | August 14, 2020 | October 2024 |
| NCT02896582 | Active, not recruiting | Phase 2 | Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance | October 2016 | March 2025 |
| NCT00551928 | Active, not recruiting | Phase 3 | Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients | June 2007 | June 2025 |
| NCT00004165 | Completed | Phase 3 | Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | October 1999 | August 2003 |
| NCT00004188 | Completed | Phase 3 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma | February 2001 | |
| NCT00004250 | Completed | Phase 2 | Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery | August 1999 | |
| NCT00004921 | Completed | Phase 3 | High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery | September 1998 | September 2007 |
| NCT00005589 | Completed | Phase 3 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | October 1999 | April 2013 |
| NCT00005792 | Completed | Phase 1 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | June 2, 1998 | November 1, 2018 |
| NCT00005803 | Completed | Phase 1/Phase 2 | Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma | September 1999 | October 2018 |
| NCT00005835 | Completed | Phase 1 | N99-02: Melphalan and Buthionine Sulfoximine | August 2001 | April 2016 |
| NCT00005978 | Completed | Phase 1 | N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma | May 2000 | |
| NCT00006244 | Completed | Phase 2 | Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma | February 2000 | April 2016 |
| NCT00006695 | Completed | Phase 2 | Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma | April 1, 2000 | December 16, 2014 |
| NCT00006747 | Completed | Phase 2 | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma | November 2000 | February 2003 |
| NCT00007852 | Completed | Phase 2 | Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma | September 1, 2000 | January 1, 2011 |
| NCT00007995 | Completed | Phase 2 | Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis | July 1999 | May 2008 |
| NCT00008190 | Completed | Phase 2 | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia | March 1999 | May 2008 |
| NCT00008229 | Completed | Phase 3 | Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | August 2000 | September 2001 |
| NCT00008268 | Completed | Phase 2 | Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma | August 2000 | June 2003 |
| NCT00012051 | Completed | Phase 3 | Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma | September 2000 | October 2007 |
| NCT00014469 | Completed | Phase 2 | Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer | December 2000 | May 2007 |
| NCT00014508 | Completed | Phase 2 | Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | November 19, 2001 | May 27, 2011 |
| NCT00017225 | Completed | Phase 2 | Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma | May 1997 | February 2002 |
| NCT00017368 | Completed | Phase 2 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma | April 2001 | January 2012 |
| NCT00017680 | Completed | Phase 2 | Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis | July 1999 | April 2004 |
| NCT00019097 | Completed | Phase 2 | Vaccine Therapy in Treating Patients With Multiple Myeloma | July 1995 | March 2007 |
| NCT00019760 | Completed | Phase 2 | Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver | April 1999 | March 2002 |
| NCT00019786 | Completed | Phase 2 | Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases | August 1999 | January 2006 |
| NCT00019968 | Completed | Phase 2 | Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg | August 1999 | March 2002 |
| NCT00020501 | Completed | Phase 3 | Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver | March 2001 | January 2005 |
| NCT00025649 | Completed | Phase 2 | Combination Chemotherapy Followed by Surgery and Peripheral Stem Cell or Bone Marrow Transplantation in Treating Infants With Newly Diagnosed Neuroblastoma | July 1999 | March 2009 |
| NCT00027560 | Completed | Phase 2 | Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer | July 2001 | April 2009 |
| NCT00027937 | Completed | Phase 2 | Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma | August 2001 | November 2007 |
| NCT00028600 | Completed | Phase 2 | Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma | November 2001 | February 2010 |
| NCT00030082 | Completed | Phase 1 | Hepatic Arterial Infusion With Melphalan in Treating Patients With Unresectable Liver Cancer | July 2001 | |
| NCT00038831 | Completed | Phase 1/Phase 2 | Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS | May 2001 | October 2006 |
| NCT00038857 | Completed | Phase 2 | Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases | September 2001 | June 2009 |
| NCT00040937 | Completed | Phase 2 | S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma | June 2002 | October 2015 |
| NCT00043979 | Completed | Phase 2 | Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas | September 19, 2002 | December 14, 2011 |
| NCT00045136 | Completed | Phase 1/Phase 2 | Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | January 2002 | |
| NCT00046852 | Completed | Phase 1/Phase 2 | Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma | December 2001 | February 2008 |
| NCT00054353 | Completed | Phase 1/Phase 2 | Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma | October 2002 | October 14, 2012 |
| NCT00055653 | Completed | Phase 2 | Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders | January 2003 | September 2005 |
| NCT00058292 | Completed | Phase 1 | Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | April 2000 | March 2009 |
| NCT00060255 | Completed | Phase 2 | High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors | December 1991 | February 2013 |
| NCT00064337 | Completed | Phase 2 | S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis | January 2004 | November 2015 |
| NCT00067002 | Completed | Phase 2 | Randomized Double Cord Blood Transplant Study | April 2003 | July 2016 |
| NCT00070187 | Completed | Phase 2/Phase 3 | Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma | November 2003 | |
| NCT00070200 | Completed | Phase 1 | Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma | March 2004 | December 2013 |
| NCT00075621 | Completed | Phase 2 | Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis | August 2000 | September 4, 2020 |
| NCT00080886 | Completed | Phase 2 | Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma | May 8, 2002 | March 12, 2015 |
| NCT00083551 | Completed | Phase 3 | UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy | August 1998 | August 2014 |
| NCT00083915 | Completed | Phase 3 | DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation | June 2001 | June 2010 |
| NCT00089167 | Completed | Phase 2 | Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis | May 2002 | |
| NCT00089401 | Completed | Phase 2 | Isolated Hepatic Perfusion With Melphalan in Treating Patients With Unresectable Colorectal Cancer That Has Metastasized to the Liver | July 2004 | March 2008 |
| NCT00089453 | Completed | Phase 1 | Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant | September 2003 | May 2010 |
| NCT00096083 | Completed | Phase 2 | Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer | September 2004 | August 2012 |
| NCT00103298 | Completed | Phase 2 | Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer | December 2004 | July 2006 |
| NCT00104975 | Completed | Phase 1 | Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | February 2005 | May 2008 |
| NCT00112645 | Completed | Phase 1 | Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors | April 2005 | February 2011 |
| NCT00112827 | Completed | Phase 1/Phase 2 | Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma | November 2004 | February 15, 2019 |
| NCT00133367 | Completed | Phase 2 | Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus | August 2005 | November 2011 |
| NCT00137995 | Completed | Phase 3 | R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma | June 2003 | October 2008 |
| NCT00165139 | Completed | Phase 2 | Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas | January 1996 | February 2009 |
| NCT00176865 | Completed | Phase 2 | Stem Cell Transplant for Immunologic or Histiocytic Disorders | August 2002 | August 2014 |
| NCT00177047 | Completed | Phase 2/Phase 3 | Autologous Transplant for Multiple Myeloma | April 20, 2004 | August 1, 2020 |
| NCT00182793 | Completed | Phase 2 | Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer | July 2005 | October 2014 |
| NCT00185614 | Completed | Phase 2 | Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma | August 2000 | April 2010 |
| NCT00202917 | Completed | Phase 1/Phase 2 | Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies | February 2004 | December 2010 |
| NCT00205764 | Completed | Phase 3 | Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy | March 1999 | October 2009 |
| NCT00217438 | Completed | Phase 3 | Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma | July 2005 | |
| NCT00233987 | Completed | Phase 2 | S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma | October 2005 | December 2017 |
| NCT00238433 | Completed | Phase 2 | Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma | March 2005 | December 2016 |
| NCT00244946 | Completed | Phase 1 | Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma | March 2004 | March 2013 |
| NCT00248430 | Completed | Phase 1/Phase 2 | Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer | August 2003 | July 2007 |
| NCT00253435 | Completed | Phase 2 | N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma | September 2005 | December 2013 |
| NCT00265889 | Completed | Phase 2 | Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma | February 2002 | April 2010 |
| NCT00275015 | Completed | Phase 2 | Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia | January 1998 | April 2012 |
| NCT00276809 | Completed | Phase 2 | Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia | June 2001 | September 2004 |
| NCT00303849 | Completed | Phase 1/Phase 2 | Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors | September 15, 2005 | March 12, 2021 |
| NCT00305812 | Completed | Phase 2 | Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma | March 9, 2006 | June 30, 2008 |
| NCT00307086 | Completed | Phase 2 | Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants | June 2005 | March 2012 |
| NCT00313625 | Completed | Phase 2 | Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma | September 2005 | |
| NCT00317811 | Completed | Phase 2 | Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma | November 2005 | |
| NCT00324727 | Completed | Phase 3 | Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma | February 2006 | August 2012 |
| NCT00325416 | Completed | Phase 1/Phase 2 | Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma. | November 19, 2001 | January 30, 2018 |
| NCT00344526 | Completed | Phase 3 | Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis | January 2000 | June 2006 |
| NCT00349778 | Completed | Phase 2 | High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma | August 2006 | April 2010 |
| NCT00357396 | Completed | Phase 2 | Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors | June 2005 | October 2009 |
| NCT00365755 | Completed | Phase 3 | Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma | March 2008 | |
| NCT00383448 | Completed | Phase 2 | HSCT for High Risk Inherited Inborn Errors | September 2006 | September 2014 |
| NCT00385788 | Completed | Phase 2 | Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease | July 2005 | August 2016 |
| NCT00388635 | Completed | Phase 1/Phase 2 | Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients. | April 2004 | December 2008 |
| NCT00392691 | Completed | Phase 1 | Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment | October 2006 | May 2013 |
| NCT00405756 | Completed | Phase 3 | A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. | January 2007 | April 2016 |
| NCT00406978 | Completed | Phase 1/Phase 2 | Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients | February 2006 | April 2014 |
| NCT00410982 | Completed | Phase 1 | Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies | December 2006 | September 2012 |
| NCT00421811 | Completed | Phase 1/Phase 2 | A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan | April 2007 | March 2009 |
| NCT00423514 | Completed | Phase 1/Phase 2 | Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease | November 20, 2006 | June 18, 2021 |
| NCT00423709 | Completed | N/A | Allogeneic Blood Stem Cell Transplantation | January 1998 | August 2007 |
| NCT00427557 | Completed | Phase 2 | Cellular Therapy With Cord Blood Cells | October 2006 | November 2010 |
| NCT00427765 | Completed | Phase 2 | Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma | December 2004 | November 2010 |
| NCT00429572 | Completed | Phase 2 | Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer | January 1998 | May 2008 |
| NCT00439556 | Completed | Phase 2 | Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant | February 13, 2007 | June 7, 2018 |
| NCT00454480 | Completed | Phase 2/Phase 3 | Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | August 2006 | |
| NCT00469209 | Completed | Phase 1/Phase 2 | Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients | June 2006 | December 2008 |
| NCT00472056 | Completed | Phase 2 | Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies | March 2005 | June 2012 |
| NCT00477035 | Completed | Phase 1 | Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies | May 2006 | March 2011 |
| NCT00477750 | Completed | Phase 1/Phase 2 | Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma | June 2005 | August 5, 2013 |
| NCT00477815 | Completed | Phase 1 | Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma | May 31, 2005 | May 7, 2018 |
| NCT00477971 | Completed | Phase 3 | Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis | October 2005 | December 2014 |
| NCT00482846 | Completed | Phase 1 | Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma | June 2007 | September 2012 |
| NCT00498316 | Completed | Phase 1 | Cord Blood Expansion on Mesenchymal Stem Cells | July 3, 2007 | October 2016 |
| NCT00505895 | Completed | Phase 2 | FM 140 vs FM100 Study in Patients With Multiple Myeloma | January 2002 | May 2013 |
| NCT00506129 | Completed | Phase 2 | Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma | September 2003 | June 2015 |
| NCT00507416 | Completed | Phase 3 | Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone | June 2007 | March 2013 |
| NCT00520767 | Completed | Phase 2 | Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease | September 2007 | June 6, 2019 |
| NCT00521014 | Completed | Phase 2 | GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma | October 2007 | July 2013 |
| NCT00536601 | Completed | N/A | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors | June 29, 2006 | July 9, 2018 |
| NCT00536978 | Completed | Phase 2 | Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies | September 2007 | November 2010 |
| NCT00544570 | Completed | N/A | High-Dose Chemotherapy in Treating Patients Undergoing Stem Cell Transplant for Recurrent or Refractory Hodgkin's Lymphoma | April 1998 | December 2007 |
| NCT00547196 | Completed | N/A | AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders | August 16, 2005 | May 28, 2024 |
| NCT00550784 | Completed | Phase 1 | Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | January 2001 | October 2014 |
| NCT02497404 | Completed | Phase 2 | Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR | February 13, 2015 | June 17, 2021 |
| NCT00001576 | Completed | Phase 1 | A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver | July 1997 | March 2002 |
| NCT00001587 | Completed | Phase 1 | A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver | September 1997 | March 2001 |
| NCT00002548 | Completed | Phase 3 | SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma | January 1994 | November 2006 |
| NCT00002556 | Completed | Phase 3 | Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma | July 1994 | |
| NCT00002594 | Completed | Phase 2 | Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors | September 1994 | March 2007 |
| NCT00002601 | Completed | Phase 2 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma | September 1994 | September 2014 |
| NCT00002630 | Completed | Phase 2 | High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse | June 1993 | May 2001 |
| NCT00002678 | Completed | Phase 3 | Combination Chemotherapy in Treating Patients With Multiple Myeloma | June 2, 1995 | December 21, 2009 |
| NCT00002680 | Completed | Phase 2 | Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer | February 1994 | December 2000 |
| NCT00002730 | Completed | Phase 1 | Chemotherapy in Treating Children With Neuroblastoma | June 1996 | |
| NCT00002750 | Completed | Phase 1 | Melphalan in Patients With Neoplastic Meningitis | December 1992 | May 2001 |
| NCT00002802 | Completed | Phase 3 | Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma | July 1990 | September 2003 |
| NCT00002810 | Completed | Phase 2 | High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis | May 1996 | May 2006 |
| NCT00002835 | Completed | Phase 3 | Combination Chemotherapy in Treating Patients With Lymphoma | October 30, 1995 | February 4, 2004 |
| NCT00002945 | Completed | Phase 3 | High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia | December 1996 | August 2011 |
| NCT00002973 | Completed | Phase 2 | Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma | December 1995 | December 2000 |
| NCT00002977 | Completed | Phase 1 | Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission | January 1997 | |
| NCT00002982 | Completed | Phase 2 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma | January 1997 | October 2005 |
| NCT00003007 | Completed | Phase 2 | Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma | July 1996 | January 2004 |
| NCT00003080 | Completed | Phase 1 | Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer | September 1996 | May 2001 |
| NCT00003081 | Completed | Phase 1 | Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Ewing's Sarcoma, Peripheral Primitive Neuroectodermal Tumor, or Rhabdomyosarcoma | March 1998 | January 2002 |
| NCT00003146 | Completed | Phase 2 | Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | November 1997 | June 2001 |
| NCT00003199 | Completed | Phase 2 | Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer | November 1997 | December 2009 |
| NCT00003215 | Completed | Phase 3 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma | April 1997 | March 2004 |
| NCT00003335 | Completed | Phase 2 | Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer | January 1998 | January 2012 |
| NCT00003336 | Completed | Phase 2 | Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions | January 1998 | February 2006 |
| NCT00003353 | Completed | Phase 2 | High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis | November 16, 1998 | |
| NCT00003392 | Completed | Phase 2 | High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer | September 1997 | January 2003 |
| NCT00003396 | Completed | Phase 2 | Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer | September 1998 | December 2002 |
| NCT00003397 | Completed | Phase 2 | Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma | September 1998 | December 2002 |
| NCT00003399 | Completed | Phase 2 | Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma | September 1998 | September 2002 |
| NCT00003400 | Completed | Phase 2 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer | September 1998 | March 2000 |
| NCT00003401 | Completed | Phase 2 | Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma | January 1999 | September 2002 |
| NCT00003402 | Completed | Phase 2 | Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | January 1999 | December 2002 |
| NCT00003413 | Completed | Phase 2 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer | September 1998 | February 2001 |
| NCT00003416 | Completed | Phase 2 | S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia | September 1998 | January 2004 |
| NCT00003425 | Completed | Phase 1/Phase 2 | Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect | December 1997 | |
| NCT00003554 | Completed | Phase 2 | Rituximab in Treating Patients With Multiple Myeloma | November 1998 | April 2004 |
| NCT00003631 | Completed | Phase 2 | Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma | August 1998 | |
| NCT00003632 | Completed | Phase 2 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma | September 1998 | |
| NCT00003661 | Completed | Phase 2 | Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer | June 1998 | March 2006 |
| NCT00003662 | Completed | Phase 2 | Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases | August 1998 | January 2001 |
| NCT00003727 | Completed | Phase 2 | Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia | March 1999 | February 2008 |
| NCT00003789 | Completed | Phase 3 | Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg | March 1999 | |
| NCT00003816 | Completed | Phase 2/Phase 3 | Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer | October 19, 1998 | July 12, 2019 |
| NCT00003899 | Completed | Phase 1 | Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors | January 1999 | November 2001 |
| NCT00003954 | Completed | Phase 1/Phase 2 | Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma | March 1999 | |
| NCT00003957 | Completed | Phase 2 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | December 1998 | August 2001 |
| NCT00003972 | Completed | Phase 3 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer | July 1998 | March 2003 |
| NCT00004056 | Completed | Phase 1 | Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia | October 1999 | March 2007 |
| NCT00004088 | Completed | Phase 2 | Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma | April 13, 1999 | January 9, 2018 |
| NCT00004158 | Completed | Phase 1/Phase 2 | Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | June 1999 | January 2006 |
| NCT00556127 | Completed | Phase 2 | Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma | June 2002 | September 2006 |
| NCT00564200 | Completed | Phase 2 | MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning | November 2007 | October 2014 |
| NCT00565968 | Completed | Phase 1 | Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg | October 2007 | |
| NCT00566098 | Completed | Phase 1/Phase 2 | Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma | November 2007 | October 2018 |
| NCT00567567 | Completed | Phase 3 | Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma | November 5, 2007 | March 31, 2022 |
| NCT00574496 | Completed | Phase 2 | Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma | November 13, 2007 | August 2, 2022 |
| NCT00577096 | Completed | N/A | Effects of Exercise in Combination With Epoetin Alfa | October 2001 | June 2004 |
| NCT00577278 | Completed | Phase 2 | A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan | October 3, 2007 | December 14, 2023 |
| NCT00589563 | Completed | Phase 2 | Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer | May 2007 | February 2012 |
| NCT00591630 | Completed | Phase 2 | Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation | November 14, 2007 | March 5, 2020 |
| NCT00602706 | Completed | Phase 1/Phase 2 | Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant | January 2000 | July 2010 |
| NCT00621400 | Completed | Phase 1/Phase 2 | Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis | January 2008 | December 2009 |
| NCT00641030 | Completed | Phase 1 | Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes | July 2007 | January 2011 |
| NCT00651937 | Completed | Phase 2 | Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden | March 2008 | January 2016 |
| NCT00661544 | Completed | Phase 1/Phase 2 | Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients | March 2004 | June 2007 |
| NCT00679367 | Completed | Phase 2 | Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis | May 2008 | May 2015 |
| NCT00683046 | Completed | Phase 2 | T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies | November 2001 | December 2014 |
| NCT00691015 | Completed | Phase 2 | Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant | May 2008 | April 2014 |
| NCT00695409 | Completed | Phase 2 | Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma | March 18, 2008 | March 27, 2017 |
| NCT00734149 | Completed | Phase 2 | Bortezomib With Melphalan and Prednisone for Multiple Myeloma | July 2004 | February 2008 |
| NCT00743288 | Completed | Phase 1/Phase 2 | Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma | July 2008 | December 2012 |
| NCT00784823 | Completed | Phase 1/Phase 2 | Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma | January 2007 | December 2013 |
| NCT00789256 | Completed | N/A | Low Dose Melphalan and Bortezomib for AML and High-Risk MDS | September 2004 | December 2008 |
| NCT00790647 | Completed | Phase 2 | Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis | June 2008 | November 2014 |
| NCT00792142 | Completed | Phase 2 | Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma | January 16, 2008 | April 21, 2014 |
| NCT00793572 | Completed | Phase 2 | Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma | October 2008 | October 2016 |
| NCT00793845 | Completed | Phase 2 | Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma | August 2008 | January 2018 |
| NCT00824135 | Completed | Phase 1 | Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies | January 2009 | December 2016 |
| NCT00840684 | Completed | Phase 1/Phase 2 | Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia | January 2009 | |
| NCT00856388 | Completed | N/A | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders | January 14, 2009 | March 13, 2019 |
| NCT00890500 | Completed | Phase 1 | Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies. | January 2011 | October 2013 |
| NCT00890552 | Completed | N/A | A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis | April 2009 | October 2012 |
| NCT00899847 | Completed | Phase 2 | Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG | May 2009 | December 2014 |
| NCT00911859 | Completed | Phase 2 | A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients | June 2009 | April 2013 |
| NCT00916058 | Completed | Phase 1/Phase 2 | Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma | April 23, 2009 | March 1, 2018 |
| NCT00936936 | Completed | Phase 2 | High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors | June 2, 2009 | January 11, 2024 |
| NCT00943592 | Completed | Phase 1/Phase 2 | Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies | March 2006 | November 2013 |
| NCT00948922 | Completed | Phase 2 | Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma | June 18, 2009 | May 14, 2019 |
| NCT00968760 | Completed | Phase 1 | CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies | June 20, 2011 | April 23, 2020 |
| NCT00985959 | Completed | Phase 1 | A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT) | July 2008 | June 2010 |
| NCT00992446 | Completed | Phase 2 | Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | September 2, 2010 | October 29, 2019 |
| NCT01008462 | Completed | Phase 2 | Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia | March 18, 2010 | June 30, 2018 |
| NCT01010217 | Completed | Phase 2 | Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide | November 5, 2009 | October 5, 2017 |
| NCT01035463 | Completed | Phase 1/Phase 2 | Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma | November 12, 2009 | July 27, 2018 |
| NCT01039025 | Completed | Phase 2 | TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma | February 18, 2002 | May 19, 2006 |
| NCT01045460 | Completed | Phase 2 | Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma | January 15, 2010 | June 2020 |
| NCT01078454 | Completed | Phase 3 | Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis | November 2010 | November 27, 2012 |
| NCT01079936 | Completed | Phase 1/Phase 2 | Lenalidomide and High-Dose Melphalan | March 2010 | March 2015 |
| NCT01083316 | Completed | Phase 2 | Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis | September 2009 | September 4, 2020 |
| NCT01119066 | Completed | Phase 2 | HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies | May 3, 2010 | March 30, 2021 |
| NCT01141712 | Completed | Phase 2 | Autologous Transplant in HIV Patients (BMT CTN 0803) | April 2010 | June 2016 |
| NCT01200329 | Completed | Phase 2 | High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease | June 2011 | December 6, 2018 |
| NCT01237249 | Completed | Phase 2 | Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone | February 2011 | May 2016 |
| NCT01237951 | Completed | Phase 2 | High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma | November 8, 2010 | September 20, 2017 |
| NCT01256398 | Completed | Phase 2 | Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | December 14, 2010 | November 15, 2021 |
| NCT01279694 | Completed | Phase 1/Phase 2 | Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP) | October 2010 | February 2014 |
| NCT01335685 | Completed | Phase 1/Phase 2 | Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma | June 27, 2011 | December 29, 2016 |
| NCT01341262 | Completed | Phase 2 | THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM) | March 2002 | January 2009 |
| NCT01408563 | Completed | Phase 2 | Reduced Intensity Double Umbilical Cord Blood Transplantation | December 2011 | June 2017 |
| NCT01413178 | Completed | Phase 3 | A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma | September 30, 2011 | March 10, 2019 |
| NCT01421173 | Completed | Phase 1 | Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies | August 2011 | September 2015 |
| NCT01471067 | Completed | Phase 1 | Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies | July 13, 2012 | April 25, 2017 |
| NCT01505569 | Completed | N/A | Auto Transplant for High Risk or Relapsed Solid or CNS Tumors | October 20, 2011 | February 1, 2024 |
| NCT01526603 | Completed | N/A | High Dose Chemotherapy and Autologous Transplant for Neuroblastoma | March 28, 2012 | May 30, 2023 |
| NCT01529827 | Completed | Phase 2 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | February 28, 2012 | August 29, 2019 |
| NCT01538472 | Completed | Phase 1/Phase 2 | Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma | September 2003 | November 2011 |
| NCT01605032 | Completed | Phase 2 | Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma | February 2012 | March 2018 |
| NCT01625351 | Completed | Phase 1 | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | August 20, 2012 | February 10, 2020 |
| NCT01626092 | Completed | N/A | Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders | July 11, 2012 | November 2013 |
| NCT01690143 | Completed | Phase 1/Phase 2 | Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation | May 2012 | November 1, 2017 |
| NCT01702831 | Completed | Phase 2 | Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance | October 1, 2013 | July 31, 2022 |
| NCT01702961 | Completed | N/A | Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease | June 2002 | January 2017 |
| NCT01731886 | Completed | Phase 4 | Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma | September 2012 | April 11, 2017 |
| NCT01807611 | Completed | Phase 2 | Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy | May 16, 2013 | September 27, 2021 |
| NCT01818752 | Completed | Phase 3 | Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma | July 8, 2013 | November 4, 2016 |
| NCT01824693 | Completed | Phase 2 | Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia | June 24, 2013 | December 31, 2017 |
| NCT01842308 | Completed | Phase 1/Phase 2 | Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma | June 4, 2013 | October 28, 2019 |
| NCT01849783 | Completed | Phase 2 | Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma | April 4, 2013 | September 30, 2020 |
| NCT01877837 | Completed | Phase 3 | Stem Cell Transplantation for Sickle Cell Anemia | June 2011 | September 2021 |
| NCT01904136 | Completed | Phase 1/Phase 2 | Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia | April 22, 2014 | February 28, 2022 |
| NCT01916252 | Completed | Phase 3 | Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old | September 2013 | November 16, 2016 |
| NCT01921387 | Completed | Phase 1/Phase 2 | Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies | October 9, 2013 | July 26, 2020 |
| NCT01936090 | Completed | Phase 1 | Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma | August 2013 | February 16, 2018 |
| NCT01983969 | Completed | Phase 1/Phase 2 | Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma | November 7, 2013 | November 22, 2017 |
| NCT01998503 | Completed | Phase 3 | Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis | December 2007 | August 2013 |
| NCT01998971 | Completed | Phase 1 | A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma | February 18, 2014 | January 11, 2024 |
| NCT02007863 | Completed | N/A | Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia | August 2008 | June 2014 |
| NCT02043847 | Completed | Phase 1 | Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Relapsed or Refractory Multiple Myeloma (BMT-03) | January 14, 2014 | September 14, 2016 |
| NCT02059239 | Completed | Phase 1/Phase 2 | Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma | June 4, 2014 | June 15, 2020 |
| NCT02072863 | Completed | Phase 1/Phase 2 | A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma | January 2014 | September 2015 |
| NCT02097134 | Completed | Phase 1 | Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma | October 31, 2014 | September 30, 2023 |
| NCT02130869 | Completed | Phase 1 | A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas | October 10, 2014 | December 20, 2017 |
| NCT02197221 | Completed | Phase 3 | Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma | January 2015 | December 31, 2018 |
| NCT02206425 | Completed | Phase 1/Phase 2 | Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients | September 2014 | March 6, 2018 |
| NCT02331368 | Completed | Phase 2 | Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma | June 2015 | June 2017 |
| NCT02390544 | Completed | Phase 1 | A Pharmacokinetic Study of Melphalan in Children | May 8, 2015 | September 23, 2018 |
| NCT02435901 | Completed | Phase 1/Phase 2 | HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity | December 2008 | December 2019 |
| NCT02440464 | Completed | Phase 2 | Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) | August 2015 | October 1, 2020 |
| NCT02472392 | Completed | Phase 1 | Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma | April 2013 | December 2016 |
| NCT02474563 | Completed | Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma | May 2011 | May 2014 | |
| NCT00001296 | Completed | Phase 3 | A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma | February 1992 | October 2000 |
| NCT02504359 | Completed | Phase 1 | Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma | July 20, 2015 | September 9, 2020 |
| NCT02506959 | Completed | Phase 2 | Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma | September 14, 2015 | June 3, 2024 |
| NCT02581007 | Completed | Phase 2 | Reduced Intensity Conditioning Transplant Using Haploidentical Donors | October 26, 2015 | December 28, 2020 |
| NCT02660281 | Completed | Phase 1 | URMC Related Haplo-identical Donor BMT | October 2015 | January 7, 2021 |
| NCT02707393 | Completed | Phase 2/Phase 3 | Allogeneic Stem Cell Transplantation for Children With CML | April 30, 2009 | December 1, 2020 |
| NCT02728102 | Completed | Phase 2 | Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) | July 2016 | December 9, 2022 |
| NCT02756572 | Completed | Phase 2 | Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms | September 22, 2016 | July 1, 2020 |
| NCT02766465 | Completed | Phase 2 | Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503) | November 2016 | May 2, 2023 |
| NCT02771197 | Completed | Phase 2 | Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant | September 28, 2016 | July 31, 2023 |
| NCT02780609 | Completed | Phase 1/Phase 2 | Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma | July 20, 2017 | February 23, 2021 |
| NCT02867800 | Completed | Phase 1 | Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease | July 2016 | December 30, 2023 |
| NCT02880293 | Completed | N/A | Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor | August 23, 2016 | November 20, 2023 |
| NCT02917096 | Completed | Phase 1 | Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis | November 13, 2016 | August 31, 2023 |
| NCT02960646 | Completed | Phase 1 | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | January 18, 2017 | February 13, 2023 |
| NCT03019640 | Completed | Phase 2 | Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma | October 10, 2017 | August 16, 2021 |
| NCT03072771 | Completed | Phase 1 | Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | August 1, 2017 | October 30, 2023 |
| NCT03096782 | Completed | Phase 2 | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma | October 13, 2017 | September 20, 2022 |
| NCT03187223 | Completed | Phase 2 | Bendamustine and Melphalan in Myeloma | July 20, 2017 | May 28, 2020 |
| NCT03217812 | Completed | Phase 3 | A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region) | November 23, 2017 | March 8, 2024 |
| NCT03393611 | Completed | Phase 1 | CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome | November 30, 2012 | November 18, 2021 |
| NCT03412565 | Completed | Phase 2 | A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens | April 26, 2018 | April 18, 2024 |
| NCT03426969 | Completed | Early Phase 1 | Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis | January 31, 2018 | September 21, 2020 |
| NCT03609827 | Completed | Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients | September 1, 2015 | May 31, 2021 | |
| NCT03792815 | Completed | Phase 2 | Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL) | October 2009 | September 2013 |
| NCT03794167 | Completed | Phase 2 | BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's Lymphoma | June 1, 2012 | November 30, 2018 |
| NCT04682405 | Completed | Phase 2 | Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM) | May 5, 2021 | November 11, 2022 |
| NCT01728051 | No longer available | Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver | |||
| NCT00799539 | No longer available | A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients | |||
| NCT06022939 | Not yet recruiting | Phase 3 | Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis | July 1, 2024 | October 29, 2030 |
| NCT06207799 | Not yet recruiting | Phase 2 | Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma | July 30, 2024 | December 31, 2031 |
| NCT05303727 | Not yet recruiting | Phase 2 | Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma | August 2022 | August 2027 |
| NCT06377540 | Not yet recruiting | Phase 2 | MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma | August 1, 2024 | September 1, 2027 |
| NCT06287944 | Not yet recruiting | Phase 1 | 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome | June 18, 2024 | February 24, 2027 |
| NCT05903937 | Not yet recruiting | Phase 1 | Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases | December 31, 2023 | December 31, 2029 |
| NCT05565105 | Not yet recruiting | Phase 2 | CD34+ Transplants for Leukemia and Lymphoma | June 2024 | June 2031 |
| NCT05863845 | Not yet recruiting | N/A | Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL | June 1, 2023 | November 30, 2025 |
| NCT05139004 | Recruiting | Phase 1 | 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome | July 19, 2022 | December 13, 2024 |
| NCT02605421 | Recruiting | Phase 2 | Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma | June 2016 | July 2025 |
| NCT04370301 | Recruiting | Phase 2 | Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis | February 9, 2021 | August 31, 2029 |
| NCT06195891 | Recruiting | Phase 1 | Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome | September 28, 2024 | June 21, 2027 |
| NCT03016806 | Recruiting | Phase 1 | Umbilical Cord Blood Transplantation From Unrelated Donors | June 2015 | June 2026 |
| NCT03602235 | Recruiting | Phase 1 | High Dose Ascorbic Acid for Plasma Cell Disorders | March 5, 2019 | August 31, 2026 |
| NCT05735717 | Recruiting | Phase 2 | MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies | May 11, 2023 | November 30, 2030 |
| NCT04384692 | Recruiting | Phase 2 | Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis | December 18, 2020 | December 31, 2029 |
| NCT00692939 | Recruiting | Phase 1/Phase 2 | Autologous Stem Cell Transplantation for Crohn's Disease | June 26, 2012 | December 2026 |
| NCT02727803 | Recruiting | Phase 2 | Personalized NK Cell Therapy in CBT | May 19, 2016 | May 31, 2025 |
| NCT05436418 | Recruiting | Phase 1/Phase 2 | The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation | November 18, 2022 | July 2, 2027 |
| NCT01962415 | Recruiting | Phase 2 | Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | February 4, 2014 | November 2024 |
| NCT05457556 | Recruiting | Phase 3 | Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome | March 15, 2023 | December 1, 2027 |
| NCT05466318 | Recruiting | Phase 3 | ChiCGB vs BEAM in High-risk or R/R Lymphomas | July 1, 2022 | December 30, 2025 |
| NCT05504291 | Recruiting | Phase 2 | A Study to Give Treatment Inside the Eye to Treat Retinoblastoma | November 4, 2022 | December 31, 2026 |
| NCT03579875 | Recruiting | Phase 2 | Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders | November 13, 2018 | January 5, 2029 |
| NCT05508009 | Recruiting | Phase 1/Phase 2 | Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor | January 10, 2023 | October 2034 |
| NCT03570983 | Recruiting | Phase 2 | A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion | September 5, 2018 | December 2024 |
| NCT05636787 | Recruiting | Phase 2 | Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients | June 6, 2023 | April 2028 |
| NCT04018937 | Recruiting | Phase 2 | Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation | March 22, 2019 | January 2027 |
| NCT02790515 | Recruiting | Phase 2 | Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation | July 14, 2016 | July 1, 2025 |
| NCT04098393 | Recruiting | Phase 1 | Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation | September 18, 2019 | September 2025 |
| NCT03494569 | Recruiting | Phase 1 | Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome | July 6, 2018 | November 11, 2028 |
| NCT06172296 | Recruiting | Phase 3 | Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | April 19, 2024 | December 31, 2029 |
| NCT01804634 | Recruiting | Phase 2 | Reduced Intensity Haploidentical BMT for High Risk Solid Tumors | March 27, 2013 | January 2030 |
| NCT04483206 | Recruiting | Phase 1 | Personalized Autologous Transplant for Multiple Myeloma | May 20, 2021 | December 31, 2026 |
| NCT04221035 | Recruiting | Phase 3 | High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) | November 5, 2019 | November 2032 |
| NCT06158828 | Recruiting | Phase 1/Phase 2 | Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML | May 15, 2024 | May 31, 2030 |
| NCT04530487 | Recruiting | Phase 2 | Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults | August 19, 2020 | May 9, 2025 |
| NCT06140966 | Recruiting | Phase 2 | Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma | October 20, 2023 | October 20, 2027 |
| NCT06028828 | Recruiting | Phase 2 | Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation | September 11, 2023 | September 2027 |
| NCT04232085 | Recruiting | Phase 2 | Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide | February 12, 2020 | December 31, 2026 |
| NCT01652092 | Recruiting | N/A | Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies | September 4, 2012 | December 2026 |
| NCT04799002 | Recruiting | Phase 3 | Topotecan and Melphalan for Retinoblastoma | March 11, 2021 | December 30, 2027 |
| NCT03856216 | Recruiting | Phase 2 | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation | October 28, 2019 | March 31, 2025 |
| NCT04812470 | Recruiting | Phase 1 | Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases | February 6, 2023 | February 2030 |
| NCT03852407 | Recruiting | Phase 2 | Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning | February 4, 2019 | November 1, 2038 |
| NCT04150042 | Recruiting | Phase 1 | SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells | January 13, 2021 | December 2025 |
| NCT03829371 | Recruiting | Phase 4 | STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA | January 3, 2019 | January 3, 2030 |
| NCT03125642 | Recruiting | Phase 2 | Auto Stem Cell Transplant for Lymphoma Patients | April 20, 2017 | April 30, 2026 |
| NCT02333162 | Recruiting | Phase 1 | Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant | December 5, 2014 | December 1, 2028 |
| NCT03118492 | Recruiting | Phase 1 | Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis | May 24, 2017 | March 24, 2025 |
| NCT00357565 | Recruiting | Phase 2 | Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia | November 2005 | December 2025 |
| NCT06001385 | Recruiting | Phase 2 | HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | December 8, 2023 | June 30, 2026 |
| NCT04937634 | Recruiting | Phase 1 | Pharmacokinetic Study of Melphalan in Pediatric Hematopoietic Stem Cell Transplantation | September 11, 2020 | September 2023 |
| NCT04982354 | Recruiting | Phase 1/Phase 2 | Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia | July 5, 2022 | August 1, 2032 |
| NCT04994977 | Recruiting | Phase 1 | Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery | May 4, 2023 | December 2026 |
| NCT03736616 | Recruiting | Phase 2 | Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL | August 16, 2019 | September 2023 |
| NCT04022239 | Recruiting | Phase 1/Phase 2 | Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant | March 13, 2020 | July 31, 2025 |
| NCT05031897 | Recruiting | Phase 2 | Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | October 25, 2021 | October 1, 2024 |
| NCT05088356 | Recruiting | Phase 1 | Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft | September 7, 2021 | December 2025 |
| NCT05115630 | Recruiting | Phase 1/Phase 2 | Off-the-shelf NK Cells + SCT for Myeloid Malignancies | April 8, 2022 | June 1, 2024 |
| NCT03073694 | Recruiting | Phase 2 | Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis | July 14, 2017 | July 2025 |
| NCT04904588 | Recruiting | Phase 2 | HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide | September 30, 2021 | July 2024 |
| NCT04903678 | Recruiting | N/A | Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma | May 1, 2021 | May 1, 2030 |
| NCT01704716 | Recruiting | Phase 3 | High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) | February 2002 | September 2026 |
| NCT05617625 | Suspended | Phase 2 | CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome | June 2024 | June 2031 |
| NCT01653418 | Terminated | Phase 2 | Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation | September 2012 | December 2013 |
| NCT01659658 | Terminated | Phase 3 | Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis | December 26, 2012 | July 11, 2022 |
| NCT04205240 | Terminated | Phase 2 | Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma | December 22, 2020 | November 22, 2021 |
| NCT01745913 | Terminated | Phase 2 | Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies | October 26, 2012 | April 29, 2015 |
| NCT01746173 | Terminated | Phase 2 | CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma | July 2013 | October 2014 |
| NCT00301860 | Terminated | N/A | Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer | January 2003 | November 2007 |
| NCT01794572 | Terminated | Phase 1/Phase 2 | Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse | April 24, 2013 | January 7, 2020 |
| NCT00290628 | Terminated | N/A | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer | October 1999 | April 2007 |
| NCT01807286 | Terminated | Phase 1 | Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis | January 2014 | February 2016 |
| NCT00281879 | Terminated | Phase 2 | Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer | February 2006 | March 2008 |
| NCT00253721 | Terminated | Phase 1 | Melphalan With BBBD in Treating Patients With Brain Malignancies | May 1998 | December 2016 |
| NCT01875237 | Terminated | Phase 1/Phase 2 | Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene | December 27, 2013 | March 7, 2017 |
| NCT00003086 | Terminated | Phase 1/Phase 2 | Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer | March 1997 | January 28, 2001 |
| NCT01907009 | Terminated | Phase 2/Phase 3 | A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP) | January 2013 | December 22, 2016 |
| NCT04412707 | Terminated | Phase 2 | A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients | August 4, 2020 | January 10, 2022 |
| NCT04455139 | Terminated | Phase 2 | A Prospective International Multicenter Clinical Trial for Eyes With Relapsed Retinoblastoma | November 15, 2021 | May 22, 2023 |
| NCT02043860 | Terminated | Phase 1 | Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma | January 10, 2014 | November 7, 2016 |
| NCT00176839 | Terminated | Phase 2/Phase 3 | Stem Cell Transplantation for Hematological Malignancies | June 7, 2000 | February 2012 |
| NCT02116959 | Terminated | Phase 1 | Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma | July 23, 2014 | May 25, 2019 |
| NCT00121186 | Terminated | Phase 2 | S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma | July 2005 | December 2011 |
| NCT02199041 | Terminated | Phase 2 | Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen | July 11, 2014 | May 23, 2017 |
| NCT02259348 | Terminated | Phase 2 | Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation | October 2014 | March 2016 |
| NCT02295722 | Terminated | Phase 1/Phase 2 | GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma | April 2015 | January 2023 |
| NCT02310997 | Terminated | Phase 2 | Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT) | July 2011 | May 2015 |
| NCT02353572 | Terminated | Phase 1/Phase 2 | Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | November 2009 | September 2011 |
| NCT02366663 | Terminated | Phase 3 | BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL | January 2015 | October 2016 |
| NCT02415036 | Terminated | Phase 2 | Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma | June 2014 | December 2018 |
| NCT00075608 | Terminated | Phase 2 | 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis | August 2001 | October 2011 |
| NCT02483000 | Terminated | Phase 1 | Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies | February 1, 2017 | September 2, 2020 |
| NCT02489500 | Terminated | Phase 3 | Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib | June 2015 | April 28, 2017 |
| NCT02589145 | Terminated | Phase 1/Phase 2 | Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype | June 22, 2016 | April 8, 2019 |
| NCT02614560 | Terminated | Phase 1/Phase 2 | A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients | November 2015 | September 14, 2017 |
| NCT02653196 | Terminated | Early Phase 1 | A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors | September 2015 | August 2017 |
| NCT02700841 | Terminated | Phase 2 | Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation | January 9, 2020 | December 21, 2022 |
| NCT02716805 | Terminated | Phase 1 | Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant | December 13, 2016 | February 16, 2018 |
| NCT02750254 | Terminated | Phase 1 | Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation | June 27, 2016 | October 14, 2020 |
| NCT02773550 | Terminated | Phase 4 | Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma | January 2014 | July 2018 |
| NCT00583622 | Terminated | Phase 2 | Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients | December 2007 | January 2012 |
| NCT00539500 | Terminated | Phase 2/Phase 3 | Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma | October 2007 | September 5, 2012 |
| NCT00618540 | Terminated | Phase 2 | Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis | January 2007 | May 2013 |
| NCT00074269 | Terminated | Phase 2 | Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer | July 2003 | March 2008 |
| NCT00623077 | Terminated | Phase 1 | MT2004-30: Tomotherapy for Solid Tumors | August 2005 | October 2016 |
| NCT00635024 | Terminated | Phase 2 | Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma | May 2008 | November 2010 |
| NCT00637767 | Terminated | Phase 2 | High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant | December 1, 2007 | October 31, 2013 |
| NCT00052884 | Terminated | Phase 1 | Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation | January 22, 2004 | March 2011 |
| NCT00681044 | Terminated | Phase 2 | HD Melphalan and SCT in Patients With IGDD or LCDD | October 2006 | January 2016 |
| NCT00793650 | Terminated | Phase 1/Phase 2 | Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study | May 2005 | September 2011 |
| NCT00800150 | Terminated | Phase 1 | Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment | November 2008 | October 2010 |
| NCT00801931 | Terminated | Phase 1/Phase 2 | Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders | September 6, 2007 | May 5, 2009 |
| NCT00827099 | Terminated | Phase 2 | Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer | June 2006 | November 2009 |
| NCT00843310 | Terminated | Phase 2 | Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma | November 2008 | October 2011 |
| NCT00523809 | Terminated | Phase 2 | Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor | August 2007 | October 2011 |
| NCT00505921 | Terminated | Phase 2 | Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma | March 2003 | November 2009 |
| NCT00916045 | Terminated | Phase 2 | Pilot Study of Unrelated Cord Blood Transplantation | September 2009 | March 2012 |
| NCT00920153 | Terminated | Phase 3 | Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma | May 2008 | March 2016 |
| NCT03259516 | Terminated | Phase 1/Phase 2 | Nivolumab With Chemotherapy in Refractory MDS | May 25, 2017 | December 25, 2018 |
| NCT00943293 | Terminated | Phase 1 | Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies | May 2003 | January 2012 |
| NCT01050764 | Terminated | Phase 1/Phase 2 | Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | June 2009 | June 2014 |
| NCT00429026 | Terminated | Phase 2 | Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation | January 2004 | March 2008 |
| NCT01116128 | Terminated | Phase 2 | Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients | February 2008 | May 2011 |
| NCT03615105 | Terminated | Phase 2 | Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors | July 25, 2018 | March 6, 2024 |
| NCT03615144 | Terminated | Phase 2 | TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors | July 23, 2018 | November 13, 2020 |
| NCT00003926 | Terminated | Phase 1 | Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | November 1998 | August 2003 |
| NCT01350258 | Terminated | Phase 1/Phase 2 | Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps | April 2011 | August 2012 |
| NCT01359254 | Terminated | Phase 2 | Cord Blood Transplantation for Patients With Cancer | April 2010 | June 2012 |
| NCT01393769 | Terminated | Phase 2 | Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage | November 2009 | May 2013 |
| NCT01453088 | Terminated | Phase 2 | Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older | June 24, 2010 | May 1, 2022 |
| NCT01500161 | Terminated | Phase 2 | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match | November 2011 | November 2013 |
| NCT01518153 | Terminated | Phase 2 | Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) | February 2012 | August 2014 |
| NCT01548573 | Terminated | Phase 2 | Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment | May 2012 | August 2014 |
| NCT01598025 | Terminated | N/A | Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor | May 2, 2012 | October 16, 2017 |
| NCT01617213 | Terminated | Phase 2 | Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma | April 2012 | |
| NCT01658904 | Terminated | Phase 1/Phase 2 | Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma | July 2012 | April 2014 |
| NCT00003815 | Unknown status | Phase 3 | Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma | June 1994 | |
| NCT00003163 | Unknown status | Phase 2 | Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers | September 1997 | |
| NCT00436761 | Unknown status | Phase 1 | Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors | May 2004 | |
| NCT00334932 | Unknown status | Phase 1/Phase 2 | Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma | February 2006 | |
| NCT00003578 | Unknown status | Phase 3 | High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma | January 1993 | |
| NCT03583424 | Unknown status | Phase 1/Phase 2 | Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma | September 10, 2018 | December 31, 2022 |
| NCT04380376 | Unknown status | Phase 2 | Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia | April 30, 2020 | October 30, 2020 |
| NCT00417053 | Unknown status | Phase 3 | Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Stem Cell Transplant | ||
| NCT00410631 | Unknown status | Phase 3 | Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma | October 2004 | |
| NCT01920516 | Unknown status | Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment | July 2013 | July 2020 | |
| NCT04264078 | Unknown status | Early Phase 1 | Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies | March 1, 2021 | June 1, 2023 |
| NCT00008307 | Unknown status | Phase 2 | Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders | April 1998 | |
| NCT00004903 | Unknown status | Phase 2 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | October 1999 | |
| NCT00181025 | Unknown status | Phase 2 | Isolated Pelvic and Limb Perfusion in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs' Girdle | May 2004 | |
| NCT00526734 | Unknown status | Phase 2 | High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma | February 2006 | |
| NCT02784054 | Unknown status | Phase 2 | Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor | April 2014 | March 2023 |
| NCT00669812 | Unknown status | Phase 2 | High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma | February 2008 | |
| NCT00030719 | Unknown status | Phase 3 | Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma | December 2001 | |
| NCT04264039 | Unknown status | Early Phase 1 | Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies | April 1, 2020 | April 1, 2022 |
| NCT00028886 | Unknown status | Phase 3 | Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma | March 2001 | |
| NCT02784015 | Unknown status | Phase 2 | Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma | May 2016 | May 2023 |
| NCT00550992 | Unknown status | N/A | Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia | January 2006 | |
| NCT00526318 | Unknown status | N/A | Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma | January 2007 | |
| NCT00720447 | Unknown status | Phase 2 | Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma | November 2008 | |
| NCT00747877 | Unknown status | Phase 3 | High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy | April 2008 | |
| NCT00025636 | Unknown status | Phase 3 | Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma | July 2001 | |
| NCT02544425 | Unknown status | Phase 2 | VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT) | February 21, 2016 | November 30, 2021 |
| NCT03061656 | Unknown status | Phase 2 | Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma | January 1, 2009 | December 31, 2018 |
| NCT01572688 | Unknown status | N/A | Safety and Efficacy Study of High Dose Melphalan to Treat Multiple Myeloma | November 2011 | June 2014 |
| NCT00317408 | Unknown status | N/A | Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma | April 2004 | |
| NCT00084695 | Unknown status | Phase 2 | Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases | September 2003 | |
| NCT00209222 | Unknown status | Phase 3 | Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL | July 2004 | December 2014 |
| NCT00002599 | Unknown status | Phase 3 | Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma | September 1994 | |
| NCT00025103 | Unknown status | Phase 2 | Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney | May 2001 | |
| NCT00907036 | Unknown status | Phase 2 | Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma | July 2009 | |
| NCT00908180 | Unknown status | Phase 2 | Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | July 2009 | |
| NCT00003603 | Unknown status | Phase 3 | Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma | March 1998 | |
| NCT00025064 | Unknown status | Phase 2 | Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma | January 2000 | |
| NCT04278040 | Unknown status | Phase 2 | Inhalations of Ultra-low Doses of Melphalan for the Treatment of Non-cystic Fibrosis Bronchiectasis | June 20, 2018 | December 30, 2021 |
| NCT00024193 | Unknown status | Phase 2 | Chemotherapy and Surgery Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Neuroblastoma | April 1999 | |
| NCT00020566 | Unknown status | Phase 3 | Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma | February 2001 | |
| NCT00016887 | Unknown status | Phase 3 | Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma | December 2000 | |
| NCT00983398 | Unknown status | Phase 1/Phase 2 | Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors | July 9, 2009 | December 31, 2022 |
| NCT00014339 | Unknown status | Phase 3 | Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma | March 2000 | |
| NCT03385096 | Unknown status | Phase 2/Phase 3 | Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT | January 2, 2018 | December 2021 |
| NCT02109861 | Unknown status | Early Phase 1 | Microdose Study of Melphalan, Bortezomib and Dexamethasone | January 2014 | December 2015 |
| NCT00002653 | Unknown status | Phase 3 | Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma | September 1993 | |
| NCT01619761 | Unknown status | Phase 1 | NK Cells in Cord Blood Transplantation | May 3, 2013 | November 2021 |
| NCT00002989 | Unknown status | Phase 3 | Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome | March 1997 | |
| NCT00085345 | Withdrawn | Phase 2 | Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma | ||
| NCT00504101 | Withdrawn | Phase 1 | Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma | June 2007 | June 2011 |
| NCT01795430 | Withdrawn | N/A | Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma | July 2013 | |
| NCT01055301 | Withdrawn | Phase 2 | S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | July 2011 | July 2011 |
| NCT00085449 | Withdrawn | Phase 1/Phase 2 | Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer | May 2006 | January 2007 |
| NCT02701673 | Withdrawn | Phase 1/Phase 2 | Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma | June 2016 | |
| NCT01969942 | Withdrawn | Phase 1 | A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma | April 2013 | October 2016 |
| NCT03579927 | Withdrawn | Phase 1/Phase 2 | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma | October 3, 2019 | October 3, 2019 |
| NCT02114502 | Withdrawn | Phase 2 | Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma | September 2014 | |
| NCT03100877 | Withdrawn | Phase 1/Phase 2 | Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma | January 2018 | May 24, 2020 |
| NCT02528877 | Withdrawn | Phase 1 | Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis | November 2015 | |
| NCT04282174 | Withdrawn | Phase 2 | CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies | September 2022 | March 1, 2030 |
| NCT00003435 | Withdrawn | Phase 1 | Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer | May 1998 | |
| NCT00661336 | Withdrawn | Phase 1 | A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma | April 2008 | |
| NCT00723658 | Withdrawn | Phase 2 | S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia | September 2008 | |
| NCT02961816 | Withdrawn | Phase 2 | Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma | June 2017 | June 2021 |
| NCT00968396 | Withdrawn | Phase 2 | Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts | February 2013 | |
| NCT03003728 | Withdrawn | Phase 2 | 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT) | November 1, 2019 | July 8, 2020 |
| NCT00972101 | Withdrawn | Phase 1 | Infusion of Expanded Cord Blood T Cells | September 2009 | September 2011 |
| NCT01769911 | Withdrawn | N/A | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma | February 2015 | |
| NCT02507076 | Withdrawn | N/A | Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma | April 2012 | July 2014 |
| NCT05228249 | Withdrawn | Phase 1 | Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma | April 2023 | October 1, 2027 |
| NCT00995059 | Withdrawn | Phase 1/Phase 2 | Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma | ||
| NCT01531244 | Withdrawn | Phase 1/Phase 2 | Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma | December 2014 | February 2016 |
| NCT04521946 | Withdrawn | Phase 1 | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer | January 14, 2021 | December 20, 2022 |
| NCT01251172 | Withdrawn | Phase 2 | RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | December 2010 | |
| NCT04466475 | Withdrawn | Phase 1 | Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma | January 27, 2024 | September 30, 2027 |
| NCT03506802 | Withdrawn | Phase 1 | TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma | July 10, 2018 | June 25, 2019 |
| NCT02447055 | Withdrawn | Early Phase 1 | Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma | December 2015 | June 2016 |